Cargando…
Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial
Regarding the management of suspected Non-ST-segment-elevation acute coronary syndrome (ACS), the main Biomarker-in-Cardiology (BIC)-8 randomized controlled trial study had reported non-inferiority for the incidence of major adverse cardiac events at 30 days in the Copeptin group (dual marker strate...
Autores principales: | Giannitsis, Evangelos, Garfias-Veitl, Tania, Slagman, Anna, Searle, Julia, Müller, Christian, Blankenberg, Stefan, von Haehling, Stephan, Katus, Hugo A., Hamm, Christian W., Huber, Kurt, Vollert, Jörn O., Möckel, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773592/ https://www.ncbi.nlm.nih.gov/pubmed/35053326 http://dx.doi.org/10.3390/cells11020211 |
Ejemplares similares
-
Role of Copeptin and hs-cTnT to Discriminate AHF from Uncomplicated NSTE-ACS with Baseline Elevated hs-cTnT—A Derivation and External Validation Study
por: von Haehling, Stephan, et al.
Publicado: (2023) -
Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study
por: Möckel, Martin, et al.
Publicado: (2015) -
The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke
por: He, Lanying, et al.
Publicado: (2018) -
Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome
por: Reinhold, Thomas, et al.
Publicado: (2018) -
Copeptin: Limited Usefulness in Early Stroke Differentiation?
por: von Recum, Johannes, et al.
Publicado: (2015)